Fresenius Group Overview

Results Center

To archive

Q2/20 Results

Solid H1 results in light of significant contributions to combat COVID-19 – Accelerated earnings growth expected in H2 – New FY/20 guidance incorporates estimated COVID-19 effects

  • Fresenius Medical Care with very strong earnings growth and exceptional cash flow development in Q2

  • Fresenius Kabi impacted by fewer elective procedures and easing extra demand for COVID 19 related products in Europe and the U.S.; only gradual recovery in China

  • Fresenius Helios seeing gradual return of elective procedures; Helios Germany supported by law to ease financial burden on hospitals; COVID-19 related reimbursement at Helios Spain with remaining uncertainties

  • Fresenius Vamed heavily impacted by COVID-19 related project delays and lack of post-acute care treatments

Selected Key Figures Q2/20


1 In constant currency
2 Before special items
3 Net income attributable to shareholders of Fresenius SE & Co. KGaA